8-KOther EventsExhibits & Filings

AMEREN CORP 8-K Report, Corporate Update (Aug 7, 2025)

Filed August 7, 2025For Securities:AEE

Summary

Ameren Corporation (AEE) has filed an 8-K to report on significant amendments to its Equity Distribution Sales Agreement. The company has executed a First Amendment to this agreement, which originally dates back to May 12, 2021. This amendment primarily serves to expand the company's equity distribution program, increasing the authorized aggregate gross sales price for its common stock by an additional $1,250,000,000. This expansion allows Ameren to potentially raise substantial capital through the issuance of its common stock, either directly through sales agents or via forward sale agreements with forward purchasers. Following this amendment, approximately $1,482,210,000 of common stock remains available for issuance under the program. Importantly, Ameren retains the flexibility to offer or sell shares and can suspend these activities at any time, indicating a strategic approach to capital raising based on market conditions and company needs.

Key Highlights

  • 1Ameren Corporation amended its Equity Distribution Sales Agreement, originally dated May 12, 2021.
  • 2The amendment increases the authorized aggregate gross sales price under the equity distribution program by $1,250,000,000.
  • 3Following the increase, up to $1,482,210,000 of common stock remains available for issuance under the program.
  • 4The amendment adds an additional Agent/Forward Seller and an Additional Forward Purchaser to the existing agreement.
  • 5The company can issue common stock through sales agents or enter into forward sale agreements.
  • 6Ameren has no obligation to sell any common stock and can suspend offers at any time.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Ameren Corporation's entry into a First Amendment to its Equity Distribution Sales Agreement. This amendment significantly increases the amount of capital the company can raise through the sale of its common stock.

The amendment increases the aggregate gross sales price authorized under the equity distribution program by $1,250,000,000. After this increase, approximately $1,482,210,000 worth of common stock remains available for issuance.

No, the filing clarifies that Ameren has no obligation to offer or sell any common stock under the Sales Agreement. The company retains the discretion to suspend offers or sales at any time, indicating this is a tool for potential future capital raising rather than a commitment to issue shares.

The agreement involves Ameren Corporation as the issuer, with a group of investment banks acting as sales agents and forward sellers. Additionally, several financial institutions are listed as forward purchasers. The amendment adds new parties to these roles.